Recent News

BriaCell Announces Additional Capital Support by the CEO

Berkeley, CA and Vancouver, BC – Aug 2, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that Dr. William Williams, BriaCell’s President & CEO, has entered into a non-brokered private placement (the “Offering”) of 4,058,441 units […]

Recent News

BriaCell Appoints Top Oncologist and Opens Second Clinical Site for its Ongoing Clinical Trial in Advanced Breast Cancer

Berkeley, CA and Vancouver, BC – July 31, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce the opening of a new clinical site, Florida Cancer Care in Plantation, FL and the appointment of Dr. Elizabeth Tan-Chiu, […]

News and Events, Recent News

BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals

Berkeley, CA and Vancouver, BC – July 24, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that it has entered into a definitive share exchange agreement (the “Share Exchange Agreement”) with its wholly-owned subsidiary, BriaCell Therapeutics […]

News and Events, Recent News

BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer

Berkeley, CA and Vancouver, BC – July 19, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, provided a clinical update regarding its US-based open-label Phase I/IIa clinical trial evaluating the safety and efficacy of BriaVax™, a genetically engineered whole-cell vaccine derived from a human breast […]

News and Events, Recent News

BriaCell Completes Manufacturing of New Batch of BriaVax™

Berkeley, CA and Vancouver, BC – July 5, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, announced today that it has successfully manufactured a new batch of its BriaVax™ vaccine, and that this new batch has passed all release testing in compliance with recent guidelines […]

Recent News

BriaCell Doses Second Patient in Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer

Berkeley, CA and Vancouver, BC – June 1, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company announced today it has enrolled the second patient in a USA-based open-label Phase I/IIa clinical trial evaluating the safety and efficacy of BriaVax™, a genetically engineered whole-cell vaccine derived […]

Recent News

BriaCell Launches Its Scientific Advisory Board

Berkeley, CA and Vancouver, BC – May 31, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), announced today the establishment of its Scientific Advisory Board (SAB) engaging a number of highly-experienced leading experts in the field of immune-oncology. Briacell is an immuno-oncology focused biotechnology company with a proprietary vaccine, Briavax™, […]